Short Bowel Syndrome clinical trials

Explore recruiting short bowel syndrome clinical trials.

Recruiting short bowel syndrome studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Short Bowel Syndrome trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A DOUBLE-BLIND PHASE 3 EXTENSION TRIAL ASSESSING THE LONG TERM SAFETY AND EFFICACY OF GLEPAGLUTIDE IN PATIENTS WITH SHORT BOWEL SYNDROME (SBS)

France, Belgium, Germany, Netherlands, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A 104-WEEK, MULTICENTER, SINGLE-ARM, LONG-TERM, PHASE 3 EXTENSION TRIAL INVESTIGATING THE SAFETY AND EFFICACY OF GLEPAGLUTIDE IN ADULT PATIENTS WITH SHORT BOWEL SYNDROME (SBS) COMPLETING THE EASE SBS 2 TRIAL

Denmark, Belgium, Germany, France, Netherlands, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A 104-week, multicenter, open-label, single-arm, phase 3 extension trial investigating the long-term safety and efficacy of Glepaglutide in adult patients with short bowel syndrome (SBS) rolling over from the EASE SBS 2 or 3 trials

Poland, France, Germany, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice-Weekly, Followed by a Long-Term, Open-Label Safety Evaluation in Patients with Short Bowel Syndrome–Intestinal Failure (SBS-IF)

Finland, France, Belgium, Germany, Hungary, Spain +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of adult patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF) without colon in continuity (CIC)

Germany, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Pharmacokinetics of apixaban in patients with short bowel syndrome requiring long-term parenteral nutrition.

Belgium

Therapeutic use (Phase IV) EU CTIS Study details

Short Bowel Syndrome trials by city

Short Bowel Syndrome in Toronto Short Bowel Syndrome in Vancouver Short Bowel Syndrome in Montreal Short Bowel Syndrome in Calgary Short Bowel Syndrome in Edmonton Short Bowel Syndrome in Ottawa Short Bowel Syndrome in Winnipeg Short Bowel Syndrome in Quebec City Short Bowel Syndrome in Hamilton Short Bowel Syndrome in Kitchener Short Bowel Syndrome in London Short Bowel Syndrome in Halifax Short Bowel Syndrome in New York Short Bowel Syndrome in Los Angeles Short Bowel Syndrome in Chicago Short Bowel Syndrome in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease